ASCO 2020 Lung Cancer In Depth

ASCO 2020 Lung Cancer In-Depth

KEYNOTE-604: Pembrolizumab Missed OS Endpoint in First-Line SCLC, but Appeared to Prolong Survival in Some Patients

The drug did, however, significantly improve progression-free survival.

Researchers Present Evidence in Support of Broad Next-Generation Sequencing in Advanced Nonsquamous NSCLC

Though they are costly, broad genetic assays that look for many gene mutations at once may confer more value overall than a one-off testing approach for patients with nsNSCLC.

Nivolumab Plus Ipilimumab Yields Long-Term Responses in Advanced NSCLC

Overall, grade 3 to 4 AEs were noted in 33% of patients receiving the immunotherapy combination vs 36% of patients receiving chemotherapy.

Bintrafusp Alfa: Durable Responses Noted in NSCLC

In the 3 ongoing responses, all had PD-L1–positive disease.

Pralsetinib Appears Promising in RET Fusion-Positive NSCLC

Three of 9 patients with measurable central nervous system metastases had an intracranial complete response, with a 56% overall response rate in this subgroup.

HER2-Positive NSCLC: Trastuzumab Deruxtecan Shows Promising Activity

Twenty-six (61.9%) patients had an ORR as confirmed by independent central review.